Clinical Trials Logo

Carcinogenesis clinical trials

View clinical trials related to Carcinogenesis.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT06339684 Active, not recruiting - Clinical trials for HPV-Related Cervical Carcinoma

HPV Immunological Markers of Cervical Persistent Infection and Oncogenesis

HPVImmuno
Start date: March 8, 2023
Phase:
Study type: Observational [Patient Registry]

The aim of this observational study is to build an immunological assay to quantify an immunoscore system for clinical practice, which could identify HPV lesions with a risk of persistent cervical infection, which represents the main predictive factor of neoplastic evolution. A pattern of host immunological factors and HPV-related parameters, in order to identify an algorithm of risk stratification and tailoring treatment will be identified. Finally, in patients with HPV infection, a virus specific immunity after vaccination will be quantified, in order to highlight those patients who have the most significant risk of infection persistence.

NCT ID: NCT05638542 Active, not recruiting - Colorectal Cancer Clinical Trials

Comparison of Expression of Carcinogenesis-related Molecular Markers in the Patients With Colon Cancer and Polyp

Start date: March 1, 2015
Phase:
Study type: Observational

A study of carcinogenesis-related molecular markers in the patients with colorectal cancer and colorectal adenoma.

NCT ID: NCT03955510 Active, not recruiting - Colorectal Cancer Clinical Trials

Abnormal Food Timing and Circadian Dyssynchrony in Alcohol Induced Colon Carcinogenesis

AFT
Start date: July 31, 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to study the impact of Western lifestyle, including moderate alcohol consumption and delayed eating patterns on studying individuals' susceptibility to colorectal cancer. This study aims to increase our ability to identify individuals at risk for colorectal cancer in the future. Each subject will experience four conditions (each for one week in duration with a week +/- 2 days wash-out in between): (1) "right-time eating" / no alcohol, (2) "right-time eating" / with alcohol, (3) "delayed-eating" / no alcohol, (4) "delayed-eating" / with alcohol. The order of experiments will be randomized [concealed randomization]. All subjects will undergo unprepped sigmoidoscopy after each week of intervention. In Aim 2, all subjects will have an option to undergo a 24h circadian assessment in the Biological Rhythms Research Lab after each week of intervention. The Investigator will assess (i) central circadian rhythms by collecting hourly salivary samples for melatonin assays and (ii) peripheral rhythm in the intestinal tract by buccal swabs once every 2h (12 time points) as well as by rectal sampling twice (every 12 hr). For Aim 3, sigmoidoscopy without sedation will be used to obtain colonic samples as the safe method compared to colonoscopy, which has some small but finite risks associated with the procedure (e.g, bleeding or perforation) as well as sedation.

NCT ID: NCT02794428 Active, not recruiting - Gastric Cancer Clinical Trials

Chemoprevention of Gastric Carcinogenesis

Start date: September 19, 2016
Phase: Phase 2
Study type: Interventional

A clinical study of the efficacy of oral alpha-difluoromethylornithine (eflornithine or DFMO) in male and female subjects ages 30-60 with gastric premalignant lesions in two high risk regions of Latin America.